BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and provided highlights on its clinical programs. 

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks